Case Report: Percutaneous closure of patent ductus arteriosus with the KONAR-MF™ device: initial experience and results at 6 months in a tertiary center

By
Alex Ismael Catalán Cabrera
Mónica Karem Medina Durand
Karen del Rosario Condori Alvino
Cesar Augusto Puma Laura
Norma Maribel Portilla Marroquin
June 1, 2026
0 min

Frontiers In Pediatrics

Overview

This report evaluates the initial outcomes of the KONAR-MF™ device for percutaneous closure of patent ductus arteriosus (PDA) in a cohort of 17 patients, highlighting its potential as a viable option for complex anatomies and underweight patients. Six-month follow-up data indicate successful closure with manageable complications.

Background

Patent ductus arteriosus (PDA) is a common congenital heart defect that can lead to significant morbidity, including congestive heart failure and pulmonary hypertension. Percutaneous closure is the preferred treatment modality, particularly with the advent of newer devices like the KONAR-MF™, which can accommodate a wider range of ductal morphologies. Understanding the safety and efficacy of such devices is crucial for optimizing patient outcomes in pediatric cardiology.

Data Highlights

Parameter	Median Value
Age	1 year
Weight	11 kg
Ductal Diameter	5 mm
Ductal Length	8 mm
Pulmonary Artery Pressure	25 mmHg
Fluoroscopy Time	9.7 min
Radiation Dose	46 mGy/cm²
Residual Shunt at 6 months	0%

Key Findings

The KONAR-MF™ device was used in 17 patients with a median age of 1 year and weight of 11 kg.
58.8% of patients presented with functional class III symptoms.
23.5% of patients were admitted due to severe pneumonia.
47.1% of PDAs were classified as type C according to the Krichenko classification.
23.5% of patients had a residual shunt immediately post-procedure, which resolved by 6 months.
The antegrade approach was utilized in 64.7% of procedures.

Clinical Implications

The findings suggest that the KONAR-MF™ device may be a safe and effective option for PDA closure, particularly in patients with complex anatomical considerations or those weighing less than 6 kg. Clinicians should consider this device as a viable alternative in selected cases where traditional devices may not be suitable.

Conclusion

The initial experience with the KONAR-MF™ device indicates promising outcomes for percutaneous PDA closure, warranting further investigation in larger cohorts to establish long-term safety and efficacy.